Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
Trispecific T-Cell Engager